	C 2012 Mar 31	C 2013 Mar 31	C 2014 Mar 31	C 2015 Mar 31	R 2016 Mar 31	2017 Mar 31	2018 Mar 31	2019 Mar 31	R 2020 Mar 31	R 2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31

Period length: Source:	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M IR	12M IR	12M AR	12M AR	12M AR	12M AR	12M PRESS
Total Revenue	2,087	2,485	2,877	3,090	3,347	3,891	4,123	5,514	6,301	7,143	8,184	11,174	14,756	15,262	16,927
Cost of Operating Revenue	1,165	1,413	1,632	1,705	1,788	1,956	2,290	2,692	2,915	3,367	4,020	5,464	7,053	7,448	7,647
Gross Profit	921	1,072	1,246	1,385	1,560	1,936	1,833	2,822	3,386	3,776	4,164	5,711	7,702	7,813	9,280
Gross Margin	44.2	43.1	43.3	44.8	46.6	49.7	44.5	51.2	53.7	52.9	50.9	51.1	52.2	51.2	54.8
Total Operating Expenses	1,744	2,090	2,357	2,582	2,819	3,187	3,679	4,569	5,248	6,198	6,998	9,548	12,972	13,639	15,428
Operating Profit	343	396	521	508	529	705	444	946	1,052	945	1,186	1,626	1,783	1,623	1,499
Operating Margin	16.4	15.9	18.1	16.4	15.8	18.1	10.8	17.2	16.7	13.2	14.5	14.6	12.1	10.6	8.9
Financing Income/(Expense) - Net	22	-9	4	-6	25	116	123	70	92	28	116	-426	-797	-804	-990
Profit before Taxes	393	610	538	624	751	850	610	1,215	1,215	1,147	1,190	1,064	1,609	1,887	448
Income Taxes	54	98	107	96	142	162	157	212	315	222	212	254	227	457	79
Profit after Tax	338	509	414	497	550	612	372	905	748	741	648	463	1,023	1,013	386
PAT Margin	16.2	20.5	14.4	16.1	16.4	15.7	9.0	16.4	11.9	10.4	7.9	4.1	6.9	6.6	2.3
EPS - Basic - ex Extraordinary Items	2.88	4.33	3.51	4.14	4.67	5.20	3.16	7.65	6.56	6.24	5.44	3.88	8.55	8.46	2.82
EPS - Diluted - ex Extraordinary Items	2.85	4.29	3.48	4.14	4.67	5.16	3.14	7.60	6.55	6.19	5.42	3.87	8.54	8.46	2.82
EBIT	343	396	521	508	529	705	444	946	1,052	945	1,186	1,626	1,783	1,623	1,499
EBITDA	522	581	732	729	777	982	829	1,394	1,604	1,660	2,000	2,739	3,352	3,310	3,455
EBITDA Margin	25.0	23.4	25.4	23.6	23.2	25.2	20.1	25.3	25.5	23.2	24.4	24.5	22.7	21.7	20.4

Balance Sheet

Abridged

Understanding Balance Sheet

Biocon Ltd. balance sheet covering assets, liabilities, equity and borrowings across annual and quarterly periods.

Consolidated

Standalone

Annual

Interim

	C 2012 Mar 31	C 2013 Mar 31	2014 Mar 31	R 2015 Mar 31	R 2016 Mar 31	2017 Mar 31	2018 Mar 31	C 2019 Mar 31	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31

Source:	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	PRESS
Total Current Assets	2,000	2,240	2,639	2,475	3,971	4,048	4,149	4,889	5,325	7,600	8,382	12,334	15,179	16,286	17,180
Long-Term Investments	51	51	51	20	27	166	25	179	134	748	408	788	754	747	1,685
Property Plant & Equipment - Net	1,537	1,694	2,587	3,156	3,741	4,086	4,409	5,540	7,098	7,964	9,364	10,123	11,978	13,414	14,664
Total Non-Current Assets	1,945	2,176	3,112	3,857	4,487	5,347	5,841	7,304	9,119	10,922	12,012	39,709	40,892	42,511	46,471
Total Assets	3,945	4,416	5,751	6,332	8,458	9,394	9,990	12,192	14,444	18,522	20,394	52,043	56,071	58,797	63,651
Total Current Liabilities	1,016	990	1,380	1,597	1,666	1,678	2,141	3,039	4,008	4,210	3,828	8,511	15,359	14,334	14,069
Long Term Debt	79	164	606	767	2,072	2,108	1,790	1,541	1,305	3,076	4,220	15,500	13,425	12,945	11,283
Total Non-Current Liabilities	662	666	1,262	1,360	2,493	2,502	2,200	2,447	3,053	5,805	7,096	21,043	15,437	16,751	12,960
Total Liabilities	1,678	1,656	2,642	2,958	4,159	4,180	4,341	5,486	7,061	10,015	10,924	29,554	30,796	31,085	27,029
Total Shareholders' Equity	2,272	2,695	3,027	3,262	4,034	4,838	5,181	6,098	6,706	7,627	8,433	17,867	19,784	21,644	34,032
Minority Interest	4	65	82	112	266	376	468	609	677	881	1,038	4,622	5,491	6,069	2,590
Total Equity	2,276	2,760	3,109	3,374	4,300	5,214	5,649	6,707	7,383	8,508	9,470	22,489	25,275	27,713	36,622
Total Liabilities & Equity	3,954	4,416	5,751	6,332	8,458	9,394	9,990	12,192	14,444	18,522	20,394	52,043	56,071	58,797	63,651

Cash Flow

Abridged

Understanding Cash Flow Statement

Biocon Ltd. cash flow statement covering operating, investing and financing activities across annual and quarterly periods.

Consolidated

Standalone

Annual

Interim

	2012 Mar 31	2013 Mar 31	2014 Mar 31	2015 Mar 31	R 2016 Mar 31	2017 Mar 31	2018 Mar 31	2019 Mar 31	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31

Period length: Source:	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M PRESS
Operating CF bef Changes in Working Cap	466	696	563	597	576	948	765	1,162	1,453	1,533	1,916	1,991	2,886	2,621	2,409
Working Capital - Increase/(Decrease)	98	-192	38	-354	-176	-227	-107	-29	-165	-424	-790	-501	-635	923	-1,132
Net CF from Operating Activities	564	504	600	243	400	721	659	1,133	1,288	1,109	1,127	1,490	2,251	3,544	1,277
Capital Expenditures - Net	298	361	796	917	803	762	913	1,492	1,829	1,737	1,923	1,723	1,908	2,343	1,912
Net CF from Investing Activities	-393	-416	-979	-541	-1,221	-638	-744	-793	-1,655	-3,690	-1,759	-14,405	-1,149	-351	-2,230
Dividends Paid - Cash - Total	90	100	150	105	220	-	79	79	70	-	-	72	203	83	91
Stock - Issuance/(Retirement) - Net	-	-	-	-	-5	4	17	-69	539	798	43	1,202	31	10	8,599
Debt - LT & ST - Issuance/(Retirement) - Total	-58	-4	603	327	1,343	-123	-114	8	13	1,882	309	12,405	-1,313	541	-2,663
Net Cash Flow from Financing Activities	-152	-1	427	187	1,118	-119	-176	-141	479	2,680	352	13,534	-1,485	-1,220	-58
Free Cash Flow to Equity	208	138	407	-347	940	-164	-369	-351	-529	1,255	-487	12,172	-970	1,742	-3,298
Free Operating CF net dividend	176	42	-348	-779	-624	-41	-337	-438	-619	-637	-798	-308	117	1,118	-726
Free Operating CF	266	142	-198	-674	-404	-41	-258	-359	-549	-637	-798	-236	320	1,201	-635

Business Segment Analysis

FY End:

Mar 25

Biocon Ltd. business segment breakdown covering revenue, operating income and assets across key divisions for the selected financial year.

Revenue / Sales

Biosimilers (58.5%)₹ 8,929.20 CrResearch Services (23.5%)₹ 3,585.70 CrGenerics (18.0%)₹ 2,746.80 Cr

Assets

Biosimilers (74.6%)₹ 44,440.00 CrGenerics (14.0%)₹ 8,327.10 CrResearch Services (11.4%)₹ 6,795.90 Cr

Operating Income

Biosimilers (54.6%)₹ 1,087.60 CrResearch Services (31.5%)₹ 627.90 CrGenerics (8.8%)₹ 175.50 CrUnallocate (5.1%)₹ -100.90 Cr

Regional Segment Analysis

FY End:

Mar 25

Biocon Ltd. geographic revenue split showing domestic and international market performance across revenue and income for the selected financial year.

Revenue / Sales

United States of America (36.9%)₹ 7,042.30 Cr European union (incuding Ireland) (20.1%)₹ 3,848.10 CrEuropean union (incuding Ireland) (20.1%)₹ 3,848.10 CrRest of the World (17.8%)₹ 3,394.80 CrIndia (5.1%)₹ 976.50 Cr

Historical Segment Analysis

Track how Biocon Ltd. segment contributions have evolved over multiple financial years to see which divisions are growing, shrinking or gaining strategic importance.

Capex

Sales

Assets

Operating Income

Business

Regional

Business

	2010 Mar 31	2011 Mar 31	2012 Mar 31	2013 Mar 31	2014 Mar 31

Eliminations	0	0	0	0	0
Pharma	121	335	407	291	993
Research Services	59	35	61	62	119
Unallocate	0	0	0	0	0
Discontinued Operations	-	5	0	-	-

Frequently Asked Questions

What is the revenue of Biocon Ltd.?

The latest trailing twelve month revenue of Biocon Ltd. is ₹ 16,927.00 Cr, reflecting a 1-year growth of 10.91% and a 3-year CAGR of 14.85%. Annual and quarterly revenue trends are available in the Income Statement section.

What is the net profit of Biocon Ltd.?

The latest trailing twelve month net profit (PAT) of Biocon Ltd. is ₹ 385.60 Cr, with a 3-year earnings CAGR of -10.01%. Detailed profit history across annual and quarterly periods is in the Income Statement section.

What is the EBITDA of Biocon Ltd.?

The trailing twelve month EBITDA of Biocon Ltd. is approximately ₹ 1,498.60 Cr (based on an operating margin of 8.85%). EBITDA reflects core operating profitability before interest, taxes, depreciation and amortisation.

What is the EPS of Biocon Ltd.?

The trailing twelve month Earnings Per Share (EPS) of Biocon Ltd. is 2.82. EPS trends across annual and quarterly periods are visible in the Income Statement section.

What is the debt level of Biocon Ltd.?

The debt-to-equity ratio of Biocon Ltd. stands at 0.45. The interest coverage ratio is 1.51x, reflecting the company's ability to service debt from operating earnings. The full breakdown of total borrowings is in the Balance Sheet section.

What is the book value per share of Biocon Ltd.?

The estimated book value per share of Biocon Ltd. is 208.93 (derived from a P/B ratio of 1.90 and market price of ₹ 396.90), reflecting the net asset value attributable to each share. See the Balance Sheet section for a full breakdown.

What is the cash flow from operations of Biocon Ltd.?

The trailing twelve month operating cash flow of Biocon Ltd. is ₹ 1,276.60 Cr. Annual and quarterly cash flow data is available in the Cash Flow section of the Statements tab.

Does Biocon Ltd. report consolidated or standalone financials?

Biocon Ltd. reports consolidated financials. You can toggle between consolidated and standalone views using the switch at the top of each statement section.